✦ LIBER ✦

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

✍ Scribed by M.S. Aapro; D.A. Cameron; R. Pettengell; J. Bohlius; J. Crawford; M. Ellis; N. Kearney; G.H. Lyman; V.C. Tjan-Heijnen; J. Walewski; D.C. Weber; C. Zielinski

Book ID: 116429042
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 309 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2006.05.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2010 update of EORTC guidelines for the

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

✍ M.S. Aapro; J. Bohlius; D.A. Cameron; Lissandra Dal Lago; J. Peter Donnelly; N. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 523 KB

Granulocyte-colony stimulating factor fo

Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel

✍ Jacob Gilad; Klaris Riesenberg; Wilmosh Mermershtain; Abraham Borer; Avi Porath; 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 57 KB

Use of granulocyte colony stimulating fa

Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumours in childhood

✍ Jones, Cheryl A. ;Shaw, Peter J. ;Stevens, Michael M. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 562 KB

## Abstract Children with advanced solid tumours at the Royal Alexandra Hospital for Children (RAHC) receive an intensive four drug chemotherapy combination, Super‐VAC (cyclophosphamide, 500 mg/m^2^, adriamycin, 30 mg/m^2^, actinomycin‐D, 0.5 mg/m^2^, all daily for 3 days, and vincristine, 1.5 mg/m

Primary prophylaxis with granulocyte col

Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis

✍ Sophie Lee, Angela Knox, Irene S. L. Zeng, Christin Coomarasamy, Hilary Blackloc 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 156 KB